Medically reviewed by a licensed healthcare professional. Last updated March 2026.
Wegovy (semaglutide 2.4 mg) is the FDA-approved, higher-dose version of semaglutide designed specifically for chronic weight management. Because Wegovy reaches a higher maintenance dose than Ozempic (2.4 mg vs. 2.0 mg), side effects can be more pronounced, particularly during the dose escalation phase.
If you are about to start Wegovy or you are currently titrating up and wondering whether what you are feeling is normal, this guide covers everything the clinical data tells us.
How Wegovy Dosing Works (and Why It Matters for Side Effects)
Wegovy uses a 16-week dose escalation schedule before reaching the full maintenance dose:
| Week | Dose |
|---|---|
| Weeks 1-4 | 0.25 mg |
| Weeks 5-8 | 0.5 mg |
| Weeks 9-12 | 1.0 mg |
| Weeks 13-16 | 1.7 mg |
| Week 17+ | 2.4 mg (maintenance) |
This gradual increase is not optional. It exists because clinical trials showed that jumping straight to higher doses dramatically increased the rate and severity of gastrointestinal side effects [1]. Each step gives your GLP-1 receptors and your digestive system time to adapt.
Side Effects by the Numbers: What the STEP Trials Showed
The STEP trial program (STEP 1 through STEP 5) enrolled over 5,000 participants and gives us the most comprehensive data on Wegovy side effects [1][2]:
- Nausea: 44% of Wegovy patients vs. 18% with placebo
- Diarrhea: 30% vs. 16% with placebo
- Vomiting: 24% vs. 6% with placebo
- Constipation: 24% vs. 11% with placebo
- Abdominal pain: 20% vs. 12% with placebo
- Headache: 14% vs. 12% with placebo
- Fatigue: 11% vs. 6% with placebo
These numbers are higher than what you see with Ozempic, and there is a straightforward reason: Wegovy's maintenance dose is 20% higher. The relationship between dose and GI side effects is well-established with semaglutide.
The Dose Increase Pattern
Most patients notice a predictable cycle: side effects spike for about 1 to 2 weeks after each dose increase, then gradually ease. The jump from 1.0 mg to 1.7 mg tends to be the most challenging for many patients because it is the largest percentage increase in the schedule. The final step to 2.4 mg also causes a noticeable uptick in symptoms for some people.
About 7% of participants in the STEP 1 trial discontinued due to gastrointestinal adverse events [1]. This means the vast majority (93%) were able to continue treatment despite experiencing some degree of side effects.
How Wegovy Side Effects Compare to Ozempic
Since both are semaglutide, the types of side effects are identical. The difference is intensity and frequency, driven by dosing:
| Side Effect | Ozempic (up to 2.0 mg) | Wegovy (2.4 mg) |
|---|---|---|
| Nausea | 15-20% | 44% |
| Diarrhea | 8-9% | 30% |
| Vomiting | 5-9% | 24% |
| Constipation | 3-5% | 24% |
| Discontinuation rate (GI) | ~4% | ~7% |
If you previously tolerated Ozempic well, you may still experience new or worsening symptoms when transitioning to Wegovy's higher dose. If you struggled with Ozempic at 1.0 mg, the escalation to 2.4 mg will likely be more challenging, and your provider may want to extend the time at intermediate doses.
Serious Side Effects
Wegovy carries the same serious warnings as Ozempic, since both contain semaglutide:
Pancreatitis
Acute pancreatitis occurred in 1 out of every 200-300 patients in clinical trials [1]. Severe, persistent abdominal pain radiating to the back warrants immediate medical attention and discontinuation of the drug.
Thyroid Tumors (Boxed Warning)
Same as Ozempic. Animal studies showed C-cell tumors in rodents. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 [3].
Gallbladder Disease
Cholelithiasis (gallstones) occurred at higher rates in Wegovy groups. In STEP 1, 2.6% of semaglutide patients reported gallbladder-related events vs. 1.2% with placebo [1]. Rapid weight loss from any intervention increases gallstone risk, so this is partially a downstream effect of the weight loss itself.
Suicidal Ideation
The FDA added a warning about suicidal thoughts and behavior in 2023 after post-marketing reports [4]. Large-scale analyses have not confirmed a causal link, but patients with a history of depression or suicidal ideation should be monitored closely.
Increased Heart Rate
Wegovy has been associated with a mean increase of 1 to 4 beats per minute in resting heart rate [1]. For most patients, this is clinically insignificant. However, patients with arrhythmias or other cardiac conditions should discuss this with their cardiologist.
Managing Side Effects: A Week-by-Week Strategy
Weeks 1-4 (0.25 mg): This is your adjustment period. Start making dietary changes now. Switch to smaller meals, reduce fried foods, and establish a hydration routine. Most patients have minimal symptoms at this dose.
Weeks 5-8 (0.5 mg): Nausea may start to appear. Keep bland snacks on hand (crackers, toast, plain rice). Ginger tea or ginger candies can help. Do not force yourself to eat large meals.
Weeks 9-12 (1.0 mg): This is where many patients first feel significant appetite suppression. Prioritize protein at every meal to prevent muscle loss. If nausea is severe, talk to your provider about extending this dose for an extra 2 to 4 weeks before moving up.
Weeks 13-16 (1.7 mg): The biggest dose jump in the schedule. Expect a temporary worsening of GI symptoms. Some providers prescribe anti-nausea medication (ondansetron) for short-term use during this transition.
Week 17+ (2.4 mg): You are at maintenance. For most patients, side effects have significantly improved by this point. If they have not, your provider may consider keeping you at 1.7 mg long-term if that dose is producing adequate weight loss.
When to Contact Your Provider
Reach out if you experience:
- Inability to keep down any food or liquids for more than 24 hours
- Severe abdominal pain that does not resolve
- Signs of dehydration (dark urine, dizziness, rapid heartbeat)
- Mood changes, depression, or thoughts of self-harm
- A lump or swelling in your neck
- Symptoms of gallbladder problems (sudden, intense pain in upper right abdomen)
The Bottom Line
Wegovy's side effects are real and more common than with lower-dose semaglutide formulations, but the clinical trial data shows that the overwhelming majority of patients manage them successfully. The 16-week titration schedule is your best friend. Work with your provider, do not rush through dose increases, and use the practical strategies above to minimize discomfort during the adjustment period.
Need a provider who takes a careful, patient-centered approach to Wegovy prescribing? Search our clinic directory for verified GLP-1 providers in your area.
Ready to start your weight loss journey? Find a GLP-1 clinic near you and connect with a qualified provider today.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you are experiencing a medical emergency, call 911.
Sources
- Wilding JP, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM. 2021;384:989-1002.
- Davies M, et al. "Semaglutide 2.4 mg for the Treatment of Obesity." STEP 2-5 Trials. 2021-2022.
- FDA. Wegovy Prescribing Information: Boxed Warning. 2023.
- FDA. Safety Communication: Suicidal Ideation Monitoring. 2023.